Global Genitourinary Drugs Market 2022-2028
SKU ID :TNV-13847455 | Published Date: 08-Mar-2019 | No. of pages: 125Description
TOC
PART 01: EXECUTIVE SUMMARY
PART 02: SCOPE OF THE REPORT
• 2.1 Preface
• 2.2 Preface
• 2.3 Currency conversion rates for US$
PART 03: MARKET LANDSCAPE
• Market ecosystem
• Market characteristics
• Market segmentation analysis
PART 04: MARKET SIZING
• Market definition
• Market sizing 2018
• Market size and forecast 2018-2023
PART 05: FIVE FORCES ANALYSIS
• Bargaining power of buyers
• Bargaining power of suppliers
• Threat of new entrants
• Threat of substitutes
• Threat of rivalry
• Market condition
PART 06: PIPELINE
PART 07: MARKET SEGMENTATION BY TYPE
• Market segmentation by type
• Comparison by type
• Genital diseases - Market size and forecast 2018-2023
• Urinary diseases - Market size and forecast 2018-2023
• Market opportunity by type
PART 08: CUSTOMER LANDSCAPE
PART 09: GEOGRAPHIC LANDSCAPE
• Geographic segmentation
• Geographic comparison
• North America - Market size and forecast 2018-2023
• Europe - Market size and forecast 2018-2023
• Asia - Market size and forecast 2018-2023
• ROW - Market size and forecast 2018-2023
• Key leading countries
• Market opportunity
PART 10: DECISION FRAMEWORK
PART 11: DRIVERS AND CHALLENGES
• Market drivers
• Market challenges
PART 12: MARKET TRENDS
PART 13: VENDOR LANDSCAPE
• Overview
• Landscape disruption
• Competitive scenario
PART 14: VENDOR ANALYSIS
• Vendors covered
• Vendor classification
• Market positioning of vendors
• Astellas Pharma Inc.
• AstraZeneca
• Eli Lilly and Company
• Johnson & Johnson Services, Inc.
• Novartis AG
PART 15: APPENDIX
• Research methodology
• List of abbreviations
PART 16: EXPLORE TECHNAVIO
Exhibit 01: Global pharmaceuticals market
Exhibit 02: Segments of global pharmaceuticals market
Exhibit 03: Market characteristics
Exhibit 04: Market segments
Exhibit 05: Market definition - Inclusions and exclusions checklist
Exhibit 06: Market size 2018
Exhibit 07: Global market: Size and forecast 2018-2023 ($ billions)
Exhibit 08: Global market: Year-over-year growth 2019-2023 (%)
Exhibit 09: Five forces analysis 2018
Exhibit 10: Five forces analysis 2023
Exhibit 11: Bargaining power of buyers
Exhibit 12: Bargaining power of suppliers
Exhibit 13: Threat of new entrants
Exhibit 14: Threat of substitutes
Exhibit 15: Threat of rivalry
Exhibit 16: Market condition - Five forces 2018
Exhibit 17: Global genitourinary drugs market pipeline: Overview
Exhibit 18: Global genitourinary drugs market pipeline: Overview
Exhibit 19: Type - Market share 2018-2023 (%)
Exhibit 20: Comparison by type
Exhibit 21: Genital diseases - Market size and forecast 2018-2023 ($ billions)
Exhibit 22: Syphilis cases reported in US 2013-2017
Exhibit 23: Genital diseases - Year-over-year growth 2019-2023 (%)
Exhibit 24: Urinary diseases - Market size and forecast 2018-2023 ($ billions)
Exhibit 25: Urinary diseases - Year-over-year growth 2019-2023 (%)
Exhibit 26: Market opportunity by type
Exhibit 27: Customer landscape
Exhibit 28: Market share by geography 2018-2023 (%)
Exhibit 29: Geographic comparison
Exhibit 30: North America - Market size and forecast 2018-2023 ($ billions)
Exhibit 31: North America - Year-over-year growth 2019-2023 (%)
Exhibit 32: Top 3 countries in North America
Exhibit 33: Europe - Market size and forecast 2018-2023 ($ billions)
Exhibit 34: Europe - Year-over-year growth 2019-2023 (%)
Exhibit 35: Top 3 countries in Europe
Exhibit 36: Asia - Market size and forecast 2018-2023 ($ billions)
Exhibit 37: Asia - Year-over-year growth 2019-2023 (%)
Exhibit 38: Top 3 countries in Asia
Exhibit 39: ROW - Market size and forecast 2018-2023 ($ billions)
Exhibit 40: ROW - Year-over-year growth 2019-2023 (%)
Exhibit 41: Top 3 countries in ROW
Exhibit 42: Key leading countries
Exhibit 43: Market opportunity
Exhibit 44: Prevalence of various genitourinary cancers in US 2015
Exhibit 45: Prevalence rate of urinary incontinence in the geriatric population in the US (2010)
Exhibit 46: Global geriatric population in the last 5 years
Exhibit 47: Trending advanced diagnostics
Exhibit 48: Recent approvals of generic drugs
Exhibit 49: Devices for the treatment of genitourinary diseases
Exhibit 50: Impact of drivers and challenges
Exhibit 51: Trending novel formulations
Exhibit 52: Vendor landscape
Exhibit 53: Landscape disruption
Exhibit 54: Vendors covered
Exhibit 55: Vendor classification
Exhibit 56: Market positioning of vendors
Exhibit 57: Astellas Pharma Inc. - Vendor overview
Exhibit 58: Astellas Pharma Inc. - Business segments
Exhibit 59: Astellas Pharma Inc. - Organizational developments
Exhibit 60: Astellas Pharma Inc. - Geographic focus
Exhibit 61: Astellas Pharma Inc. - Key offerings
Exhibit 62: Astellas Pharma Inc. - Key customers
Exhibit 63: AstraZeneca - Vendor overview
Exhibit 64: AstraZeneca - Business segments
Exhibit 65: AstraZeneca - Organizational developments
Exhibit 66: AstraZeneca - Geographic focus
Exhibit 67: AstraZeneca - Key offerings
Exhibit 68: AstraZeneca - Key customers
Exhibit 69: Eli Lilly and Company - Vendor overview
Exhibit 70: Eli Lilly and Company - Business segments
Exhibit 71: Eli Lilly and Company - Organizational developments
Exhibit 72: Eli Lilly and Company - Geographic focus
Exhibit 73: Eli Lilly and Company - Segment focus
Exhibit 74: Eli Lilly and Company - Key offerings
Exhibit 75: Eli Lilly and Company - Key customers
Exhibit 76: Johnson & Johnson Services, Inc. - Vendor overview
Exhibit 77: Johnson & Johnson Services, Inc. - Business segments
Exhibit 78: Johnson & Johnson Services, Inc. - Organizational developments
Exhibit 79: Johnson & Johnson Services, Inc. - Geographic focus
Exhibit 80: Johnson & Johnson Services, Inc. - Segment focus
Exhibit 81: Johnson & Johnson Services, Inc. - Key offerings
Exhibit 82: Johnson & Johnson Services, Inc. - Key customers
Exhibit 83: Novartis AG - Vendor overview
Exhibit 84: Novartis AG - Business segments
Exhibit 85: Novartis AG - Organizational developments
Exhibit 86: Novartis AG - Geographic focus
Exhibit 87: Novartis AG - Segment focus
Exhibit 88: Novartis AG - Key offerings
Exhibit 89: Novartis AG - Key customers
Exhibit 90: Validation techniques employed for market sizing
Tables & Figures
Companies
Astellas Pharma Inc.
AstraZeneca
Eli Lilly and Company
Johnson & Johnson Services, Inc.
Novartis AG
- PRICE
-
$2500$4000